ODM-203, a novel, selective and balanced FGFR and VEGFR inhibitor with strong anti-tumor activity in FGFR- and VEGFR-dependent cancer models

被引：0
|
作者：
Holmstrom, T. [1 ]
Moilanen, A. [1 ]
Linnanen, T. [1 ]
Wohlfahrt, G. [1 ]
Karlsson, S. [1 ]
Oksala, R. [1 ]
Korjamo, T. [1 ]
Bjorkman, M. [1 ]
Samajadar, S. [2 ]
Rajagopalan, S. [2 ]
Chelur, S. [2 ]
Narayan, K. [2 ]
Ramachandra, R. [2 ]
Anthony, T. [2 ]
Ds, S. [2 ]
Ramachandra, M. [2 ]
Kallio, P. [2 ]
机构：
[1] Orion Pharma, R&D Oncol Res, Turku, Finland
[2] Aurigene Discovery Technol Ltd, Res, Bangalore, Karnataka, India
来源：
EUROPEAN JOURNAL OF CANCER | 2014年 / 50卷
关键词：
D O I：
10.1016/S0959-8049(14)70558-1
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
432
引用
收藏
页码：142 / 142
页数：1
相关论文
共 46 条
  • [1] ODM-203, a novel, selective and balanced FGFR and VEGFR inhibitor with strong activity on primary and metastatic tumor growth in FGFR-dependent and angiogenic cancer models
    Holmstrom, Tim
    Moilanen, Anu
    Bjorkman, Mari
    Linnanen, Tero
    Wohlfahrt, Gerd
    Karlsson, Stefan
    Oksala, Riikka
    Korjamo, Timo
    Samajdar, Susanta
    Rajagopalan, Srinivasan
    Chelur, Shekar
    Narayan, Kishore
    Ramachandra, Raghuveer
    Anthony, Thomas
    Samiulla, D. S.
    Ramachandra, Murali
    Kallio, Pekka
    CANCER RESEARCH, 2015, 75
  • [2] ODM-203, a Selective Inhibitor of FGFR and VEGFR, Shows Strong Antitumor Activity, and Induces Antitumor Immunity
    Holmstrom, Tim H.
    Moilanen, Anu-Maarit
    Ikonen, Tarja
    Bjorkman, Mari L.
    Linnanen, Tero
    Wohlfahrt, Gerd
    Karlsson, Stefan
    Oksala, Riikka
    Korjamo, Timo
    Samajdar, Susanta
    Rajagopalan, Srinivasan
    Chelur, Shekar
    Narayanan, Kishore
    Ramachandra, Raghuveer K.
    Mani, Jiju
    Nair, Rashmi
    Gowda, Nagaraj
    Anthony, Thomas
    Dhodheri, Samiulla
    Mukherjee, Subhendu
    Ujjinamatada, Ravi K.
    Srinivas, Nanduri
    Ramachandra, Murali
    Kallio, Pekka J.
    MOLECULAR CANCER THERAPEUTICS, 2019, 18 (01) : 28 - 38
  • [3] Phase 1 study of ODM-203, a selective dual FGFR/VEGFR inhibitor, in patients with advanced solid tumours
    Rodon, J.
    Peltola, K.
    Azaro, A.
    Alvarez, E. Castanon
    Garratt, C.
    Leskinen, H.
    Bjorklund, H.
    Ruck, A.
    Massard, C.
    Bono, P.
    ANNALS OF ONCOLOGY, 2016, 27
  • [4] Dose escalation study of ODM-203, a selective dual FGFR/VEGFR inhibitor, in patients with advanced solid tumours.
    Ahnert, Jordi Rodon
    Garratt, Chris
    Laapas, Kaisa
    Leskinen, Hanna
    Bjorklund, Harry
    Ruck, Angela
    Peltola, Katriina
    Azaro, Analia
    Castanon-Alvarez, Eduardo
    Massard, Christophe
    Bono, Petri
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [5] Phase I/II study of ODM-203, a selective dual FGFR/VEGFR inhibitor, in patients with advanced solid tumours
    Bono, P.
    Massard, C.
    Peltola, K.
    Azaro, A.
    Italiano, A.
    Kristeleit, R. S.
    Lassen, U. N.
    Arkenau, H-T.
    Hakulinen, P.
    Garratt, C.
    Ikonen, T.
    Mustonen, M.
    Rodon, J.
    ANNALS OF ONCOLOGY, 2018, 29
  • [6] Nonclinical activity of the FGFR, VEGFR and PDGFR inhibitor lucitanib in FGFR3 translocated tumor models
    Minh Nguyen
    Lin, Kevin K.
    Burbridge, Mike F.
    Simmons, Andrew D.
    Harding, Thomas C.
    CANCER RESEARCH, 2015, 75
  • [7] Preclinical activity of the VEGFR, FGFR and PDGFR inhibitor lucitanib in FGFR2 aberrant endometrial and gastric cancer models
    Guffanti, F.
    Chila, R.
    Bello, E.
    Ceriani, L.
    Zangarini, M.
    Zucchetti, M.
    Saba, C.
    Jacquet-Bescond, A.
    Pierrat, M.
    Damia, G.
    EUROPEAN JOURNAL OF CANCER, 2014, 50 : 110 - 110
  • [8] SIGNIFICANT ANTITUMOR ACTIVITY OF E-3810, A NOVEL FGFR AND VEGFR INHIBITOR, IN PATIENTS WITH FGFR1 AMPLIFIED BREAST CANCER
    Dienstmann, R.
    Andre, F.
    Soria, J.
    Tabernero, J.
    De Braud, F. G. M.
    Cereda, R.
    Bahleda, R.
    Hollebecque, A.
    Delmonte, A.
    Camboni, M. G.
    ANNALS OF ONCOLOGY, 2012, 23 : 116 - 117
  • [9] Anti-tumor activity of infigratinib, a potent and selective inhibitor of FGFR1, FGFR2 and FGFR3, in FGFR fusion-positive cholangiocarcinoma and other solid tumors
    Li, Gary
    Krook, Melanie
    Roychowdhury, Sameek
    Avogadri, Francesca
    Ye, Yining
    Moran, Susan
    CANCER RESEARCH, 2019, 79 (13)
  • [10] Dovitinib (TKI258), a dual inhibitor of FGFR and VEGFR, induces tumor growth suppression in xenograft models of human bladder cancer
    Shi, Michael M.
    Linnartz, Ronald
    Versace, Richard
    Brueggen, Joseph
    Chatenay-Rivauday, Christian
    Stamm, Christelle
    Dugan, Margaret
    Porta, Diana Graus
    CANCER RESEARCH, 2011, 71
12345